$RAPH
Raphael Pharmaceutical Inc.

2023 Q4 Form 10-Q Financial Statement

#000121390023086894 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $510.0K $293.0K
YoY Change 53.61% 248.81%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $510.0K $293.0K
YoY Change 53.61% 248.81%
Operating Profit -$729.0K -$419.0K
YoY Change -48.88% -31.54%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $4.000K $2.000K
YoY Change -123.53% -113.33%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$725.0K -$417.0K
YoY Change -49.76% -33.49%
Net Earnings / Revenue
Basic Earnings Per Share $0.04 $0.03
Diluted Earnings Per Share $0.03
COMMON SHARES
Basic Shares Outstanding 18.10M shares 16.44M shares 16.08M shares
Diluted Shares Outstanding 16.44M shares 16.11M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $230.0K $299.0K $111.0K
Short-Term Investments
Other Short-Term Assets $107.0K $103.0K $7.000K
YoY Change 148.84% 296.15% -88.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $337.0K $402.0K $118.0K
YoY Change 1.81% 237.82% -39.8%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.000K $1.000K $1.000K
YoY Change 0.0% -50.0%
TOTAL ASSETS
Total Short-Term Assets $337.0K $402.0K $118.0K
Total Long-Term Assets $2.000K $1.000K $1.000K
Total Assets $339.0K $403.0K $119.0K
YoY Change 1.8% 233.06% -39.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.00K $478.0K $180.0K
YoY Change -68.28% 161.2% 130.77%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $72.00K $478.0K $180.0K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$7.310M -$7.432M -$6.707M
YoY Change 21.33% 51.0% 92.79%
Common Stock $7.577M $181.0K $164.0K
YoY Change 4726.11% 16.77% 14.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$267.0K -$75.00K -$61.00K
YoY Change
Total Liabilities & Shareholders Equity $339.0K $403.0K $119.0K
YoY Change 1.8% 233.06% -39.29%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$725.0K -$417.0K
YoY Change -49.76% -33.49%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13921106 shares
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53002
dei Entity Registrant Name
EntityRegistrantName
Raphael Pharmaceutical Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0204284
dei Entity Address Address Line1
EntityAddressAddressLine1
4 Lui Paster Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Tel Aviv-Jaffa
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6803605
dei City Area Code
CityAreaCode
(+972)
dei Local Phone Number
LocalPhoneNumber
52-775-5072
dei Security12b Title
Security12bTitle
N/A
dei Trading Symbol
TradingSymbol
N/A
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18102418 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
299000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
288000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
103000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
43000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
402000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
331000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2000 usd
CY2023Q3 us-gaap Assets
Assets
403000 usd
CY2022Q4 us-gaap Assets
Assets
333000 usd
CY2023Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
438000 usd
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
224000 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
40000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
478000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
227000 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18102418 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18102418 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15624040 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15624040 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
181000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
157000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7176000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5975000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7432000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6026000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-75000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
106000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
403000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
333000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
917000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
502000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
510000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
332000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
489000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1711000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
219000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1094000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1406000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2213000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-729000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1426000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-42000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1406000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2255000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-725000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1443000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.1
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16174658 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16444399 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15061902 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
106000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
314000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-681000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-61000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
711000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-725000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-75000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
128000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
602000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
290000 usd
us-gaap Net Income Loss
NetIncomeLoss
-812000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
118000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
63000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1200000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1443000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-62000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1406000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2255000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1490000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-40000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-243000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
251000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
40000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1115000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-482000 usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1126000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
424000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1126000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
424000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
288000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
153000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
299000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93000 usd
raph Receivables On Account Of Stock
ReceivablesOnAccountOfStock
100000 usd
CY2020Q4 raph Issued And Outstanding Share Capital Percentage
IssuedAndOutstandingShareCapitalPercentage
0.90 pure
CY2020Q4 raph Common Stock Percentage
CommonStockPercentage
0.10 pure
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100 shares
CY2021Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
9459253 shares
CY2021Q2 raph Issued And Outstanding Share Capital Percentage
IssuedAndOutstandingShareCapitalPercentage
0.90 pure
CY2021Q2 us-gaap Shares Issued
SharesIssued
1051028 shares
CY2021Q2 raph Common Stock Percentage
CommonStockPercentage
0.10 pure
CY2023Q3 us-gaap Retained Earnings Unappropriated
RetainedEarningsUnappropriated
7432000 usd
CY2023Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
255750 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.13
CY2023Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
117000 usd
CY2023Q1 us-gaap Equity Method Investment Quoted Market Value
EquityMethodInvestmentQuotedMarketValue
250000 usd
CY2023Q2 raph Company Raised Amount
CompanyRaisedAmount
190000 usd
CY2023Q2 us-gaap Transfer To Investments
TransferToInvestments
123000 usd
CY2023Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
201000 shares
CY2023Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
200000 usd
CY2023Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
180 usd
CY2023Q3 us-gaap Transfer To Investments
TransferToInvestments
80 usd
CY2023Q3 us-gaap Construction Contractor Receivable Retainage
ConstructionContractorReceivableRetainage
100 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16444399 shares
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
usd
raph Receivables On Account Of Stock
ReceivablesOnAccountOfStock
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001415397

Files In Submission

Name View Source Status
raph-20230930_lab.xml Edgar Link unprocessable
0001213900-23-086894-index-headers.html Edgar Link pending
0001213900-23-086894-index.html Edgar Link pending
0001213900-23-086894.txt Edgar Link pending
0001213900-23-086894-xbrl.zip Edgar Link pending
f10q0923ex31-1_raphaelpharma.htm Edgar Link pending
f10q0923ex31-2_raphaelpharma.htm Edgar Link pending
f10q0923ex32-1_raphaelpharma.htm Edgar Link pending
f10q0923ex32-2_raphaelpharma.htm Edgar Link pending
f10q0923_raphaelpharma.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
f10q0923_raphaelpharma_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
raph-20230930.xsd Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
raph-20230930_cal.xml Edgar Link unprocessable
raph-20230930_def.xml Edgar Link unprocessable
raph-20230930_pre.xml Edgar Link unprocessable